PPCB ▲ +6.0% - Propanc Biopharma, Inc. $PPCB - Propanc Biopharma Reports Preclinical Data with PRP & PRP plus TGF-? Inhibitor on TGF-? Pathway in Pancreatic Cancer 02-NOV-2026 08:30 AM ET